Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell...
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
About this item
Full title
Author / Creator
Publisher
Singapore: Springer Nature Singapore
Journal title
Language
English
Formats
Publication information
Publisher
Singapore: Springer Nature Singapore
Subjects
More information
Scope and Contents
Contents
Background
Despite high response rates to initial therapy, most patients with mantle cell lymphoma (MCL) experience relapsed or refractory (R/R) disease. Here, we report the efficacy, safety, and pharmacokinetics of the Phase 2, single-arm M20-075 study (NCT04477486) of ibrutinib and venetoclax combination therapy in Japanese patients with R/R M...
Alternative Titles
Full title
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2918141438
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2918141438
Other Identifiers
ISSN
1341-9625,1437-7772
E-ISSN
1437-7772
DOI
10.1007/s10147-023-02443-6
